Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

NCT00593554 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplasia
Chronic Myeloid Leukemia

Interventions

RADIATION: Total Body Irradiation
DRUG: Thiotepa
DRUG: Fludarabine
BIOLOGICAL: Rabbit ATG
DRUG: Palifermin

Sponsor

Sherif S. Farag